Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03313635 · ClinicalTrials.gov registry record
Evaluation of Prealbumin Levels in Men With Low-T
A clinical trial, sponsored by Beckman Coulter.
- Completed
- Registry status
- 19
- Enrollment target
NCT03313635: Completed study, sponsored by Beckman Coulter.
NCT03313635 is a clinical trial that has completed, run by Beckman Coulter. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03313635 has completed, sponsored by Beckman Coulter.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This is a single-center study intended to evaluate prealbumin (transthyretin), a marker of anabolic metabolism, in men with androgen deficiency (Low-T). There is emerging evidence that prealbumin is an indicator of anabolic, versus catabolic, metabolism, and that lower levels may be associated with hypogonadism.
Primary Outcome
Evaluation of prealbumin levels in subjects presenting for evaluation of possible late onset adult hypogonadism diagnosed with and without Androgen Deficiency (AD)
Interventions
- DIAGNOSTIC_TEST Men presenting with low-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-09-08 |
| Est. Completion | 2017-12-31 |
What the finished NCT03313635 record still lists
NCT03313635 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Men presenting with low-T is the first listed.
NCT03313635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03313635 about?
NCT03313635 is a clinical study titled "Evaluation of Prealbumin Levels in Men With Low-T". This is a single-center study intended to evaluate prealbumin (transthyretin), a marker of anabolic metabolism, in men with androgen deficiency (Low-T). There is emerging evidence that prealbumin is an indicator of anabolic, versus catabolic, metabolism, and that lower levels may be associated with ...
What is the current status of trial NCT03313635?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2017-09-08. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT03313635?
The interventions under investigation include: Men presenting with low-T (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03313635?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI